Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLAR BEAR: R-MINI-CHOP versus R-MINI-CHP + polatuzumab vedotin in very elderly or frail patients with diffuse large B-cell lymphoma
2022-502887-19-00Phase 3Authorised
- Sponsor
- Region Skåne
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone and 1 more in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) and 4 more (2 arms), sponsored by Region Skåne. Primary endpoint: Progression-free survival. Planned start Aug 2020; status: authorised.
02
Drugs
polatuzumab vedotinrituximabcyclophosphamidedoxorubicinprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)primary cutaneous diffuse large B-cell lymphoma (PCDLBCL)Epstein-Barr virus-positive diffuse large B-cell lymphoma
Beyond the preview
Go deeper on 2022-502887-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502887-19-00.